The results presented here indicate the necessity for extending conventional guideline-based risk stratification scores by adding novel biomarkers, such as VCAM-1, to further improve the risk stratification and guide treatment eligibility for cardiovascular disease prevention in the OSA population. This evidence concerns the gene VCAM1 and cardiovascular disorder.